Meeting
2019 ASCO Annual Meeting
Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.
Authors
Aditya Bardia
Massachusetts General Hospital Cancer Center, Boston, MA
Aditya Bardia , Sara A. Hurvitz , Angela DeMichele , Amy Sanders Clark , Amelia Bruce Zelnak , Denise A. Yardley , Meghan Sri Karuturi , Tara B. Sanft , Sibel Blau , Lowell L. Hart , Cynthia X. Ma , Nicola Caria , D. Das Purkayastha , Alomi Mistry , Stacy L. Moulder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02732119
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1016)
DOI
10.1200/JCO.2019.37.15_suppl.1016
Abstract #
1016
Poster Bd #
97
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.
First Author: Virginia F. Borges
Poster
2020 ASCO Virtual Scientific Program
Detection of actionable gene mutations in breast cancer by amplicon-based next-generation sequencing liquid biopsy.
First Author: Jing Shan Lim
Poster
2019 ASCO Annual Meeting
In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.
First Author: Yen-Shen Lu
Poster
2018 ASCO Annual Meeting
A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis.
First Author: Romualdo Barroso-Sousa